Real-World Data on Iptacopan or Atrasentan in IgA Nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is collecting real-world information from people with IgA nephropathy who are taking the medications iptacopan or atrasentan. The goal is to better understand how these treatments work in everyday medical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a kidney biopsy that confirms IgA nephropathy.
- You are 18 years or older.
- Your doctor has decided you are eligible to take iptacopan or atrasentan for your condition.
- You are not currently participating in any other research study or taking other investigational drugs.
- You do not have any medical condition or allergy that would make iptacopan or atrasentan unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (SCTC21C) for people with a type of autoimmune kidney disease called IgA nephropathy. It aims to see if the drug can reduce protein in the urine and protect kidney function.
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
This trial tests telitacicept in people with IgA nephropathy that has not responded well to standard care. It aims to reduce harmful kidney inflammation and protein leakage in the urine.
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
This study uses a mobile app to track how IgA nephropathy (IgAN) affects daily life and what treatments people use. It’s open to patients and their caregivers to help researchers learn more about the disease.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.